These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16879900)

  • 1. An effective serogroup B meningococcal vaccine.
    Domínguez F; Menéndez J; Ochoa R
    Vaccine; 2006 Nov; 24(49-50):7025-6. PubMed ID: 16879900
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
    Ochoa-Azze RF; García-Imía L; Vérez-Bencomo V
    MEDICC Rev; 2018 Jul; 20(3):22-29. PubMed ID: 31242158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neisseria meningitidis. The pathophysiological role of lipopolysaccharides in association with meningococcal disease and septic shock].
    Pedersen MØ; Pedersen DS; Pedersen M; Penkowa M
    Ugeskr Laeger; 2008 Feb; 170(6):421-6. PubMed ID: 18252172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing a new group B meningococcus vaccine.
    Isaacs D; McVernon J
    BMJ; 2014 Apr; 348():g2415. PubMed ID: 24696308
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6835; author reply 6835-6. PubMed ID: 17875437
    [No Abstract]   [Full Text] [Related]  

  • 10. Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B.
    Davenport V; Groves E; Horton RE; Hobbs CG; Guthrie T; Findlow J; Borrow R; Naess LM; Oster P; Heyderman RS; Williams NA
    J Infect Dis; 2008 Sep; 198(5):731-40. PubMed ID: 18636953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 12. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
    Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
    Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
    Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
    Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 19. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.